Skip to main content

Remote Job Finders (RJF)

Biotechs Secure Alternative Fill/Finish Capacity Amid Scrutiny of Novo Site

Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by quality problems at an ex-Catalent facility in Indiana. Novo Nordisk, meanwhile, has been tight-lipped about whether its own FDA applications have been affected.

As New Hereditary Angioedema Drugs Flood the Market, Will Uptake Match Innovation?

This year has seen the approval of several first-in-class therapies for HAE, but in a fragmented space, experts question whether they will be enough to net their developers a significant share of the entrenched market.
Scroll to top